PTGER1 Antibody

What is PTGER1 and why is it a significant research target?

PTGER1 (Prostaglandin E Receptor 1, Subtype EP1) is a 42kDa G protein-coupled receptor that mediates responses to prostaglandin E2 (PGE2). It functions through G(q) proteins which activate a phosphatidylinositol-calcium second messenger system. PTGER1 plays important roles in renal function and smooth muscle contractile responses to PGE2 in various tissues . Research targeting PTGER1 is significant for understanding inflammatory processes, pain signaling, and various physiological responses mediated by prostaglandin signaling.

What applications are PTGER1 antibodies commonly validated for?

Based on current validation data, PTGER1 antibodies are primarily validated for:

• Western blotting (WB)

• Enzyme-linked immunosorbent assay (ELISA)

• Immunohistochemistry (IHC, IHC-P, IHC-fro)

• Immunocytochemistry (ICC)

• Immunofluorescence (IF, IF-cc, IF-p)

• Fluorescence-activated cell sorting (FACS)

Different antibodies may be optimized for different applications, so researchers should select antibodies specifically validated for their experimental needs.

What species reactivity is available for PTGER1 antibodies?

Commercial PTGER1 antibodies demonstrate reactivity primarily with:

• Human

• Mouse

• Rat

Many antibodies show cross-reactivity between these species, but specific epitope recognition may vary . Always verify the specific reactivity of your selected antibody before designing cross-species experiments.

What are the optimal dilution ranges for different applications of PTGER1 antibodies?

Optimal dilutions vary by application and specific antibody:

• Western blot: 1/500-1/2000

• ELISA: ~1 μg/ml

• Immunohistochemistry: Application-specific (e.g., 17 μg/ml for some antibodies)

• Immunofluorescence: Typically 1/200-1/500

These ranges are guidelines; optimal dilutions should be determined empirically for each experimental system .

What immunogen design approaches have been successful for PTGER1 antibody production?

Successful PTGER1 antibodies have been generated using several immunogen strategies:

• Synthetic peptides corresponding to specific regions (e.g., C-terminus, internal regions)

• Peptides conjugated to carrier proteins (e.g., Keyhole Limpet Hemocyanin)

• Specific amino acid sequences (e.g., AA 61-160, AA 300-400, AA 380-402)

• Cytoplasmic domain-specific peptides

For researchers developing custom antibodies, targeting conserved domains may enhance cross-species reactivity, while targeting unique epitopes may improve specificity.

What controls should be included when validating a new PTGER1 antibody for research?

Rigorous validation requires:

• Positive controls: Cell lines with confirmed PTGER1 expression (e.g., human 293T, PC-3, HEL cell lysates)

• Negative controls: Samples lacking PTGER1 or with PTGER1 knockdown

• Blocking peptide controls: Pre-incubation with immunizing peptide should abolish signal

• Secondary antibody-only controls: To detect non-specific binding

• Cross-reactivity assessment: Testing against related prostaglandin receptors (EP2, EP3, EP4)

Validation across multiple techniques strengthens confidence in antibody specificity and sensitivity .

How can researchers distinguish between different EP receptor subtypes when using antibodies?

Distinguishing between EP receptor subtypes (EP1-EP4) requires:

• Using highly specific antibodies validated against all EP receptor subtypes

• Implementing pharmacological approaches with specific antagonists:

  • SC19220 for PTGER1 selective antagonism

  • AH6809 for PTGER2 antagonism

• Confirming results with functional assays measuring distinct signaling pathways:

  • PTGER1: calcium mobilization assays

  • PTGER2: cAMP accumulation assays

• Employing receptor knockout/knockdown models as negative controls

• Using co-localization with other markers in microscopy applications

Researchers investigating multiple EP receptors should consider combination approaches rather than relying solely on antibody detection .

What strategies can overcome detection challenges in tissues with low PTGER1 expression?

For tissues with low PTGER1 expression:

• Signal amplification techniques:

  • Tyramide signal amplification (TSA) for IHC/IF

  • Enhanced chemiluminescence (ECL) with extended exposure for Western blot

• Sample enrichment:

  • Immunoprecipitation before Western blotting

  • Membrane fraction isolation to concentrate receptor proteins

• Alternative detection systems:

  • Using fluorescent-conjugated antibodies (e.g., AbBy Fluor® 647 conjugates)

  • Employing biotinylated liposome-based interaction assay (BiLIA) for GPCR detection

• Validated positive controls:

  • Including samples with known high expression

  • Using recombinant PTGER1 protein as reference standard

What methodological adaptations are needed for detecting PTGER1 in native conformations?

PTGER1, being a GPCR with seven transmembrane domains, requires special considerations:

• Use of conformation-sensitive antibodies that recognize native epitopes

• Implementation of the bilayer-dialysis method for antigen preparation, which maintains protein structure during cell-free synthesis

• Gentle non-denaturing lysis buffers for sample preparation

• Avoiding harsh detergents that disrupt membrane protein structure

• Using fresh or properly preserved samples to maintain receptor conformation

• Considering native-PAGE rather than SDS-PAGE for certain applications

• Employing fixation protocols optimized for membrane proteins in IHC/IF applications

These adaptations are especially crucial when studying receptor-ligand interactions or functional aspects of PTGER1 .

How can researchers address non-specific bands in Western blot analysis of PTGER1?

Non-specific bands are common challenges with PTGER1 antibodies:

• Validation steps:

  • Verify the expected molecular weight (approximately 42 kDa)

  • Test multiple antibodies targeting different epitopes

  • Use positive control lysates with confirmed PTGER1 expression

• Protocol optimization:

  • Increase blocking duration and concentration

  • Optimize antibody dilution (typically 0.1-0.5 μg/ml for Western blot)

  • Use more stringent washing conditions

  • Adjust membrane transfer conditions for GPCRs

• Sample preparation refinements:

  • Include protease inhibitors to prevent degradation fragments

  • Consider membrane fraction enrichment to increase target:background ratio

  • Proper denaturation conditions optimized for membrane proteins

What factors might influence PTGER1 detection in different experimental systems?

Multiple factors can affect PTGER1 detection:

• Expression variability:

  • Cell type-specific expression patterns

  • Regulation by inflammatory mediators or treatment conditions

  • Developmental or disease state differences

• Technical considerations:

  • Sample preparation methods (fixation protocols, lysis conditions)

  • Antibody accessibility to epitopes in different applications

  • Buffer composition effects on antibody-antigen interaction

• Post-translational modifications:

  • Glycosylation state variations

  • Phosphorylation affecting epitope recognition

  • Receptor internalization or trafficking affecting surface detection

• Species-specific differences:

  • Human PTGER1 (402 amino acids) may have structural differences from rodent homologs

  • Epitope conservation varies across species, affecting cross-reactivity

How can researchers correlate PTGER1 protein detection with functional responses?

For meaningful interpretation of PTGER1 detection:

• Combine antibody-based detection with functional assays:

  • Calcium mobilization assays (PTGER1 functions through Gq signaling)

  • Antagonist studies (e.g., SC19220 for selective PTGER1 inhibition)

  • cAMP response element (CRE) reporter assays

• Consider coupling detection with:

  • Prostaglandin E2 stimulation experiments

  • Receptor trafficking and internalization studies

  • Co-localization with downstream signaling components

• Evaluate receptor activity alongside detection:

  • Measure downstream effectors (IP3, calcium release)

  • Assess physiological responses in relevant systems (e.g., smooth muscle contraction)

  • Compare with gene expression data for correlation

How is PTGER1 antibody detection integrated with studies of signaling pathway dynamics?

Advanced research applications include:

• Temporal signaling dynamics:

  • Time-course immunofluorescence studies following PGE2 stimulation

  • Analysis of receptor internalization and recycling

  • Correlation with calcium signaling kinetics

• Multi-parameter analyses:

  • Co-staining with phospho-specific antibodies for downstream effectors

  • Combined detection with other prostaglandin receptors

  • Integration with G-protein subunit localization

• Complex biological models:

  • Detection in 3D organoid cultures

  • Tissue-specific expression patterns in disease models

  • Correlation with functional outcomes in physiological systems

What role do PTGER1 antibodies play in investigating disease mechanisms?

PTGER1 antibodies enable investigation of:

• Cancer biology:

  • Expression analysis in neuroblastoma and other cancers

  • Correlation with prognostic markers

  • Investigation of EP1 signaling in tumor progression

• Inflammatory conditions:

  • Detection in tissue samples from inflammatory disease models

  • Analysis of receptor regulation during inflammation

  • Study of therapeutic targeting of prostaglandin signaling

• Renal physiology:

  • Investigation of PTGER1's role as a renal function modulator

  • Detection in specific nephron segments

  • Correlation with pathological states

• Reproductive biology:

  • Analysis in granulosa-lutein cells

  • Study of steroidogenic responses

  • Investigation of 11βHSD1 regulation mechanisms

What emerging methods are enhancing PTGER1 research beyond traditional antibody applications?

Cutting-edge approaches include:

• Advanced imaging techniques:

  • Super-resolution microscopy for receptor clustering analysis

  • Live-cell imaging with tagged antibody fragments

  • FRET-based approaches for receptor-protein interactions

• Novel detection systems:

  • Biotinylated liposome-based interaction assay (BiLIA) developed specifically for GPCRs

  • Cell-free protein synthesis systems for native conformation preservation

  • Proximity ligation assays for protein-protein interaction studies

• Systems biology integration:

  • Correlation with transcriptomic data across patient cohorts

  • Multi-omics approaches linking protein expression to metabolic pathways

  • Network analysis of prostaglandin signaling components

• Therapeutic development platforms:

  • Screening of selective EP1 antagonists

  • Validation of target engagement in drug development

  • Analysis of receptor regulation in response to therapeutic candidates